BLOG

pharmavoice

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

But in 2019, he walked away from all of that to become the founder and CEO of Alto Neuroscience, which the company said is “pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.”